Advancing Human-Relevant Drug Discovery Through Global Collaboration

Daxiang Biotech recently participated in BIO International Convention 2026, held from June 22–25 at the San Diego Convention Center in California, USA.

Recognized as one of the world's largest and most influential biotechnology events, BIO 2026 marked the 50^th anniversary of the global biotechnology industry. The convention brought together leaders from the pharmaceutical, biotechnology, investment, and broader life science communities, serving as a premier platform for scientific exchange, strategic partnerships, and commercial innovation.

This year's event welcomed more than 20,000 industry professionals from over 68 countries and regions, featured 1,600+ exhibitors, 150+ conference sessions, 950+ distinguished speakers, and facilitated nearly 70,000 partnering meetings, demonstrating BIO's unique role in connecting the global life sciences ecosystem.

Showcasing the IBAC^® Organoid-on-a-Chip Platform to a Global Audience

As part of the China Pavilion (Booth #3943), Mr. Yu Zhou, Co-founder, Chairman and CEO of Daxiang Biotech, led the company's international team in presenting Daxiang's proprietary technologies to pharmaceutical companies, biotechnology innovators, CROs, research institutions, and investors from around the world.

Throughout the event, Daxiang showcased its IBAC^® Organoid-on-a-Chip Platform alongside a portfolio of standardized human disease models, demonstrating solutions designed to support more predictive and human-relevant preclinical research.

The platform attracted strong interest from international visitors for its high physiological relevance, reproducibility, and standardized workflows. During the exhibition, the Daxiang team engaged in productive discussions with global pharmaceutical companies, biotechnology firms, and research organizations, exploring opportunities for future collaboration and reinforcing the company's growing presence in the rapidly evolving field of Microphysiological Systems (MPS).

Supporting the Next Generation of Drug Development

The pharmaceutical industry is undergoing a significant transformation toward more predictive, human-relevant approaches to drug discovery and development.

In recent years, regulatory agencies—including the U.S. FDA—have increasingly encouraged the adoption of New Approach Methodologies (NAMs) where scientifically validated and appropriate. Technologies such as organoids, organ-on-a-chip platforms, computational modeling, and other advanced in vitro systems are playing an increasingly important role in improving translational relevance and complementing traditional preclinical research.

Daxiang Biotech's proprietary IBAC^® Organoid-on-a-Chip Platform is well aligned with these evolving scientific and regulatory trends. By integrating human organoid technology with microfluidic engineering, the platform delivers physiologically relevant models that help address many of the limitations associated with conventional preclinical models, including species differences and limited clinical predictability.

Supported by Daxiang's continued investment in model standardization, reproducibility, and quality systems, the platform enables a broad range of applications, including:

· Preclinical efficacy evaluation

· Drug safety and toxicity assessment

· Disease modeling and mechanism studies

· Biomarker discovery

· Translational research for innovative therapeutics

Together, these capabilities help researchers and biopharmaceutical companies generate more reliable human-relevant data to support modern drug development.

Advancing Daxiang Biotech's Global Expansion

Participation in BIO 2026 represents another important milestone in Daxiang Biotech's international growth strategy.

In recent years, the company has actively participated in leading international scientific conferences and industry events, steadily expanding its global network while strengthening collaborations with pharmaceutical companies, biotechnology innovators, academic institutions, CROs, and technology partners worldwide.

Looking ahead, Daxiang Biotech remains committed to advancing next-generation organoid-on-a-chip technologies, enhancing platform standardization and product quality, expanding global research and commercial collaborations, and supporting the continued development of Microphysiological Systems (MPS).

By combining proprietary innovation with a growing international presence, Daxiang Biotech is dedicated to delivering more predictive, human-relevant solutions for drug discovery and translational research, helping accelerate biomedical innovation and contributing to the future of preclinical research worldwide.